Wanted – entrepreneurs


London – The British government has launched a new Enterprise Strategy aimed at making the UK the “best place to start and grow a business”. The 10-year strategy has been produced jointly by the Treasury and the Department for Business, Enterprise and Regulatory Reform. Areas where the government will focus its efforts are culture, knowledge, skills, access to finance, business innovation and regulatory frameworks, as well as the wider benefits of enterprise.
The strategy is the result of six months of dialogue with more than 600 businesses and business leaders. Specific proposals include one for consultation on the introduction of a new system of regulatory budgets for government departments that would set out the cost of new regulations. Plans are to reduce legislation to a minimum, including the burdens of regulation, inspection and enforcement. At the same time, essential protections are to remain in place, as well as structures for clearly communicating any changes. Innovation in the UK could also benefit from proposals to extend an additional €40 million in funding for enterprise education in primary schools and further education colleges, as well as from proposals for a national enterprise academy offering skills training and qualifications to 16- to 19-year olds.



London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...



London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...



Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...



GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...



London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...



London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...



London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...



Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues